Clinical Guideline Briefing
AHA
ACC
ACCP
ACEP
CHEST
SCAI
SHM
SIR
SVM
SVN
Acute Pulmonary Embolism In Adults
2026
Published May 17, 2026
10 min read
AHA and ACC launch 2026 guideline for Acute Pulmonary Embolism in Adults
A new clinical categorization system for acute PE refines risk stratification, enabling more precise management and expanding outpatient treatment options for low-risk patients.
Headline change
The guideline introduces a novel AHA/ACC Acute Pulmonary Embolism Clinical Categories (A-E) system for precise severity classification and risk-stratified management.
Bedside action
Utilize the new AHA/ACC PE Clinical Categories to guide risk stratification and consider outpatient management for select low-risk PE patients who meet specific criteria.
This comprehensive 2026 guideline for acute pulmonary embolism (PE) represents a de novo effort by a broad consortium of societies. It introduces a refined clinical categorization system designed to enhance the precision of severity classification, prognosis assessment, and evidence-based therapeutic decision-making. Clinicians should prepare to integrate these new categories into their diagnostic and management algorithms, particularly for risk-stratified treatment and expanded outpatient options.
How It Compares Across Societies
The 2026 AHA/ACC guideline largely aligns with the 2019 ESC recommendations on core aspects of acute PE management, but presents some notable differences in diagnostic emphasis and therapeutic preferences for specific patient populations.
ESC PE Guidelines 2019
This guideline
In patients with acute PE in AHA/ACC PE Categories A-C, quantification of angiographic thrombus burden for short-term risk stratification is not recommended (Class 3: No Benefit B-NR).
ESC PE Guidelines 2019
The ESC 2019 guideline does not explicitly recommend against quantifying angiographic thrombus burden for short-term risk stratification in the provided excerpt.
Why they differThe AHA/ACC guideline explicitly states a lack of correlation between high obstruction index and prognosis in meta-analyses, and no association with adverse events in cohort studies for lower-risk patients. ESC 2019 does not provide a similar explicit negative recommendation.
For the clinicianClinicians following AHA/ACC should avoid relying on thrombus burden quantification for short-term risk stratification in lower-risk PE, while ESC 2019 does not offer this specific guidance.
ESC PE Guidelines 2019
This guideline
For patients with a PE and with cancer who are offered anticoagulation beyond the initial treatment phase (3-6 months) into the extended treatment phase, either a DOAC or LMWH is recommended over VKA to reduce the risk of recurrent VTE (Class 1 A).
ESC PE Guidelines 2019
The ESC 2019 guideline states: 'Edoxaban or rivaroxaban should be considered as an alternative to LMWH, with the exception of patients with gastrointestinal cancer' (Class IIa).
Why they differThe AHA/ACC guideline provides a stronger recommendation (Class 1) for DOACs or LMWH over VKA, indicating a clear preference. The ESC guideline positions DOACs as an alternative to LMWH, suggesting LMWH may still be considered a primary option, and includes a specific caution for GI cancer.
For the clinicianAHA/ACC encourages a broader shift from VKA to DOACs/LMWH for extended anticoagulation in cancer, while ESC 2019 maintains LMWH as a strong baseline and suggests DOACs as an alternative with specific GI cancer caveats.
ESC PE Guidelines 2019
This guideline
The AHA/ACC guideline introduces new categories (A and B) for asymptomatic or symptomatic PE with low clinical severity, primarily focusing on outpatient management without explicitly recommending routine RV imaging for these lowest risk groups.
ESC PE Guidelines 2019
The ESC 2019 guideline states: 'Assessment of the RV by imaging or laboratory biomarkers should be considered, even in the presence of a low PESI or a sPESI of 0' (Class IIa).
Why they differESC 2019 emphasizes considering RV assessment even in clinically low-risk patients, potentially to detect occult RV dysfunction. The AHA/ACC guideline, with its new A/B categories, appears to streamline management for these lowest-risk groups towards outpatient care, implying less emphasis on routine RV imaging unless higher-risk features are present.
For the clinicianClinicians following ESC 2019 might be more inclined to perform RV assessment in low-risk PE patients, whereas AHA/ACC 2026 supports a more direct path to outpatient management for these groups if other criteria are met.
Where they agree
- Direct oral anticoagulants (DOACs) are preferred over vitamin K antagonists (VKAs) for oral anticoagulation in eligible patients.
- Multidisciplinary Pulmonary Embolism Response Teams (PERTs) are recommended or considered beneficial for managing higher-risk PE cases.
- DOACs and warfarin are contraindicated or not recommended during pregnancy due to potential fetal harm.
Practice Notes
Key practical considerations from the guideline to optimize patient care.
Do not miss
For low or intermediate clinical probability of PE, use age-adjusted D-dimer to rule out PE.
This approach effectively excludes PE and the need for imaging in appropriate patients, reducing unnecessary diagnostic procedures. Ensure the patient is not on therapeutic anticoagulation within 24 hours.
Implementation
Consider outpatient treatment for select low-risk PE (Categories A and B) patients.
Outpatient management is a reasonable option if the patient has immediate access to anticoagulation and reliable expert follow-up, demonstrating comparable outcomes to hospitalization for low-risk cases.
Do not miss
Activate a multidisciplinary Pulmonary Embolism Response Team (PERT) for patients with increased risk PE (Categories C-E).
PERT assessment is recommended to improve in-hospital clinical care delivery by expediting treatment, reducing IVC filter use, and potentially shortening hospital stays.
Implementation
Prescribe Direct Oral Anticoagulants (DOACs) over Vitamin K Antagonists (VKAs) for eligible oral anticoagulation patients.
DOACs are recommended to prevent recurrent VTE and reduce major bleeding, offering comparable efficacy with a better safety profile and ease of use compared to VKAs.
Caution
Avoid DOACs and warfarin in pregnant patients with acute PE.
These agents are potentially harmful and may result in miscarriages or fetal anomalies, making LMWH or UFH the recommended anticoagulation options during pregnancy.
Monitoring
Retrieve retrievable IVC filters as soon as the risk of PE has sufficiently decreased and anticoagulation is tolerated.
Timely retrieval minimizes long-term risks associated with prolonged indwelling time, such as DVT, filter fracture, and caval thrombosis, which do not offer mortality benefit in anticoagulated patients.
Key Recommendations
This section outlines key recommendations for the evaluation, diagnosis, and management of acute pulmonary embolism, emphasizing risk stratification and tailored therapeutic approaches. It provides actionable guidance for clinicians across various patient scenarios, from initial presentation to long-term follow-up.
Key recommendations15 highlighted
01
In adult patients with low or intermediate clinical probability of PE (<50%), use an age-adjusted D-dimer value below the threshold (age × 10 μg/L for fibrinogen equivalent units assays) to effectively exclude PE and the need for imaging.
Recommendation Class2a
Level of EvidenceB-R
EvidenceAge-adjusted D-dimer strategies are safe, with less than 2% missed VTE at 1 to 3 months, validated in prospective studies and meta-analyses. These studies excluded patients on therapeutic anticoagulation within the prior 24 hours.
For practiceSafely reduce unnecessary imaging for low-risk patients.
CaveatExcludes patients on therapeutic anticoagulation within 24 hours.
02
In patients undergoing imaging evaluation for suspected PE, CTPA is recommended in preference to a V/Q scan to confirm the diagnosis of acute PE.
Recommendation Class1
Level of EvidenceB-R
EvidenceCTPA is the standard imaging modality due to its wide availability, lower radiation exposure, and excellent diagnostic performance, with higher detection of peripheral PE compared to V/Q scans. It also allows for RV assessment and identification of alternative diagnoses.
For practicePrioritize CTPA for diagnostic imaging unless contraindicated.
CaveatV/Q scan is appropriate if CTPA cannot be performed or is not optimal.
03
In patients presenting with an acute PE who undergo CTPA, report the numerical right ventricle (RV)/left ventricle (LV) ratio (measured by internal diameter) over subjective quantification for risk stratification.
Recommendation Class1
Level of EvidenceB-R
EvidenceRV dysfunction assessed by CTPA is an independent predictor for in-hospital death, 30-day mortality, and clinical deterioration. Utilizing a cut-point of ≥1.0 for the RV/LV ratio yields good sensitivity and specificity, with the degree of RV enlargement being highly predictive.
For practiceStandardize RV/LV ratio reporting on CTPA for prognostic assessment.
04
In select patients diagnosed with acute PE in AHA ACC PE Categories A and B in a clinic or ED, when the rate of 90-day adverse outcomes is low and it aligns with patient goals., outpatient treatment is a reasonable option compared with hospitalization.
Recommendation Class2a
Level of EvidenceB-R
EvidenceRCTs and meta-analyses show no significant difference in adverse clinical outcomes between outpatient and inpatient treatment for low-risk PE, with low rates of mortality, bleeding, and recurrent VTE. Decision tools like Hestia, PESI, and sPESI can identify suitable patients.
CaveatRequires immediate access to anticoagulant medication and rapid, reliable, expert follow-up.
05
In patients with acute PE who are at increased risk of adverse outcomes (ie, AHA/ACC PE Categories C-E), a multidisciplinary PERT assessment is recommended to improve in-hospital clinical care delivery.
Recommendation Class1
Level of EvidenceB-NR
EvidencePERT implementation is associated with expedited treatment initiation, reduced time to therapeutic anticoagulation, decreased IVC filter use, and often reduced hospital and ICU length of stay in retrospective analyses and meta-analyses.
CaveatAHA/ACC PE Categories A or B with multiple comorbidities may also benefit from a PERT (e.g., Category B with intracranial hemorrhage).
06
In patients with acute PE who do not have an absolute contraindication to anticoagulation therapy, anticoagulation therapy should be initiated to reduce the risk of recurrent VTE and death.
Recommendation Class1
Level of EvidenceB-R
EvidenceThe role of anticoagulation in acute PE has been established since 1960 by small randomized trials and further supported by observational studies showing higher rates of death when acute PE is not treated.
For practicePromptly start anticoagulation unless absolutely contraindicated.
07
In patients with acute PE in AHA/ACC Categories C1-E1 who require parenteral anticoagulant therapy initially, LMWH is recommended over UFH to reduce recurrent VTE and major bleeding.
Recommendation Class1
Level of EvidenceB-R
EvidenceA meta-analysis shows that LMWH reduces recurrent VTE risk more effectively than UFH without increasing major bleeding risk. LMWHs have predictable pharmacokinetics, do not require routine monitoring, and are associated with a lower incidence of heparin-induced thrombocytopenia.
For practicePrefer LMWH for initial parenteral anticoagulation in higher-risk PE.
08
In patients with acute PE who are eligible for oral anticoagulation, DOACs are recommended over vitamin K antagonists (VKAs), unless contraindicated, to prevent recurrent VTE and reduce major bleeding.
Recommendation Class1
Level of EvidenceB-R
EvidenceMeta-analyses and systematic reviews encompassing thousands of patients in RCTs showed that DOACs generally provide comparable efficacy in preventing recurrent PE and DVT compared with LMWH bridging to VKAs, with a lower risk of major bleeding events (especially ICH).
For practiceChoose DOACs as first-line oral anticoagulation for most patients.
CaveatUnless contraindicated.
09
In patients with acute PE and established thrombotic antiphospholipid antibody syndrome, a VKA is recommended in preference to a DOAC for the prevention of venous and arterial thrombosis.
Recommendation Class1
Level of EvidenceA
EvidenceRandomized trials and meta-analyses consistently show an increased risk of subsequent arterial thrombotic events among patients with thrombotic APS who are treated with DOACs versus VKAs, especially with triple-positive antibodies.
For practiceUse VKA for patients with established thrombotic APS.
10
In patients who have had acute PE, regularly screen for PE-related symptoms and functional limitations at every visit for at least one year to detect chronic thromboembolic pulmonary disease (CTEPD) or other causes of dyspnea and functional limitation.
Recommendation Class1
Level of EvidenceC-LD
EvidenceBetween one-third and one-half of patients report dyspnea or limitations after PE. Protocols with follow-up at 2-4 months revealed that 77% of symptomatic patients had an abnormal perfusion scan or echocardiogram, emphasizing the importance of follow-up.
For practiceIntegrate symptom and functional limitation screening into post-PE follow-up.
11
In patients with a first acute PE and no major reversible risk factor, continue anticoagulation beyond the initial treatment phase (3-6 months) into the extended treatment phase to prevent recurrent VTE.
Recommendation Class1
Level of EvidenceA
EvidenceIn a study of 281 patients with unprovoked VTE, extended phase anticoagulation was associated with an 80% relative risk reduction of recurrent VTE (2.75 versus 13.54 events per 100 patient-years) with no significant increase in major bleeding.
For practicePlan for long-term anticoagulation in patients with unprovoked PE.
12
In patients with a first acute PE due to a major reversible risk factor, stop anticoagulation at the end of the initial treatment phase (3-6 months) to optimize the net clinical benefit of recurrent VTE versus bleeding.
Recommendation Class1
Level of EvidenceB-NR
EvidenceStopping anticoagulation after 3-6 months is associated with a low risk of recurrent VTE, especially if the PE occurred in the setting of a surgical risk factor. The risk of recurrence is similar whether treated for 3-6 or up to 24 months.
For practiceDiscontinue anticoagulation after 3-6 months for PE provoked by major reversible factors.
13
In patients with PE who are offered anticoagulation beyond the initial treatment phase (3-6 months), treat with a DOAC, unless contraindicated, over a VKA to reduce the risk of bleeding.
Recommendation Class1
Level of EvidenceA
EvidenceMultiple randomized trials and meta-analyses show that DOACs are noninferior to VKAs for recurrent VTE prevention and are associated with lower rates of major bleeding in the extended treatment phase.
For practicePrefer DOACs for extended anticoagulation.
CaveatUnless contraindicated.
14
In patients with PE and cancer who are offered anticoagulation beyond the initial treatment phase (3-6 months), either a DOAC or LMWH is recommended over VKA to reduce the risk of recurrent VTE.
Recommendation Class1
Level of EvidenceA
EvidenceDOACs (apixaban, rivaroxaban, edoxaban) are noninferior to LMWH with respect to recurrent VTE with a similar risk of major bleeding in cancer patients. LMWH is also associated with a lower risk of recurrent VTE compared to warfarin.
For practiceUse DOACs or LMWH for extended anticoagulation in cancer patients.
15
In patients with PE who are offered anticoagulation beyond the initial treatment phase (3-6 months) into the extended treatment phase, treat with half-dose apixaban or rivaroxaban to reduce bleeding risk.
Recommendation Class1
Level of EvidenceA
EvidenceRandomized studies (e.g., RENOVE, API-CAT) show half-dose apixaban or rivaroxaban maintains similar VTE recurrence rates while significantly reducing major or clinically relevant nonmajor bleeding compared to full dose or placebo.
For practiceConsider reduced DOAC doses for extended anticoagulation to minimize bleeding.
CaveatThese studies were powered to assess superiority over aspirin/placebo, not direct comparison of doses.
